SK Biopharmaceuticals Co Ltd
SK Biopharmaceuticals's GHG Emissions Data Preview
In 2024, SK Biopharmaceuticals completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources), Scope 2 (indirect emissions from purchased energy) and Scope 3 (indirect emissions across the value chain).
SK Biopharmaceuticals has also provided a category-level breakdown for 5 out of 15 Scope 3 emissions categories, offering greater transparency into its value chain emissions.
| Metric (tCO2e) | 2024 | 2023 | 2022 | 2021 - 2017 |
|---|---|---|---|---|
Total Scope 1 | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  b | Copy restricted. Please purchase to unlock this data.  a | 0000000 |
Total Scope 2 | ||||
Market-Based | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  a | 0000000 |
Location-Based | Copy restricted. Please purchase to unlock this data.  | Copy restricted. Please purchase to unlock this data. b | Copy restricted. Please purchase to unlock this data. b | 0000000 |
Total Scope 3 | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  b | Copy restricted. Please purchase to unlock this data.  a | 0000000 |
Total Scope 1 Revenue Intensity (tCO2e/$M) | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  b | Copy restricted. Please purchase to unlock this data.  a | 0000000 |
a
b
a
a
a
a
a
b
a
b
a
a
a
aVerified Sources Behind SK Biopharmaceuticals’s Greenhouse Gas (GHG) Emissions Data
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore SK Biopharmaceuticals’s data sources below and access millions more through our Disclosure Search.
Insights into SK Biopharmaceuticals's Operational Emissions
In 2024, the total operational greenhouse gas (GHG) emissions of SK Biopharmaceuticals amounted to 1,611 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2). a
Compared to 2023, the total operational greenhouse gas (GHG) emissions of SK Biopharmaceuticals increased by 8.92%, suggesting that the company faced challenges in reducing its emissions from its core operations. a b
SK Biopharmaceuticals's Scope 1 Emissions Over Time
- Total Scope 1
- Year-over-Year Change
What are SK Biopharmaceuticals's Scope 1 emissions?
In 2024, the total Scope 1 emissions of SK Biopharmaceuticals were 414 metric tons of CO₂ equivalent (tCO₂e). a
Has SK Biopharmaceuticals reduced its Scope 1 emissions over time?
Since 2021, SK Biopharmaceuticals's Scope 1 emissions have increased by 5.08%, reflecting a rising long-term trend in Scope 1 emissions over time. a b
Compared to the previous year (2023), SK Biopharmaceuticals's Scope 1 emissions decreased by 4.39%, highlighting the company's efforts to lower direct emissions from assets it owns or controls. a b
What are SK Biopharmaceuticals's Scope 2 emissions?
In 2024, SK Biopharmaceuticals reported Scope 2 greenhouse gas (GHG) emissions of 1,197 tCO₂e using the market-based method. a
What methodology does SK Biopharmaceuticals use for Scope 2 reporting?
In 2024, SK Biopharmaceuticals reported its Scope 2 emissions using the market-based method. a
SK Biopharmaceuticals's Scope 2 Emissions Over Time
- Total Scope 2 Location-Based
- Total Scope 2 Market-Based
Insights into SK Biopharmaceuticals's Value Chain Emissions
In 2024, SK Biopharmaceuticals reported 9,168 metric tons of CO₂ equivalent (tCO₂e) of Scope 3 greenhouse gas (GHG) emissions, representing indirect emissions across its upstream and downstream value chain. a
The 2024 disclosure of SK Biopharmaceuticals includes a breakdown across 5 of the 15 Scope 3 categories defined by the GHG Protocol, matching the level of disclosure in 2023, demonstrating consistent Scope 3 emissions reporting coverage year over year. a
SK Biopharmaceuticals's Scope 3 Emissions Over Time
- Total Scope 3
- Year-over-Year Change
What are SK Biopharmaceuticals's Scope 3 emissions?
In 2024, SK Biopharmaceuticals reported total Scope 3 emissions of 9,168 metric tons of CO₂ equivalent (tCO₂e). a
Approximately 100% of these emissions originated from upstream activities such as purchased goods and capital goods, while 0% came from downstream activities like product use, distribution, and end-of-life treatment. a
Compared to the previous year (2023), SK Biopharmaceuticals's Scope 3 emissions decreased by 22.84%, highlighting the company's efforts to lower indirect emissions from its value chain. a b
What categories of Scope 3 emissions does SK Biopharmaceuticals disclose?
In 2024, SK Biopharmaceuticals reported emissions for 5 out of the 15 Scope 3 categories defined by the GHG Protocol. a
This partial disclosure allows for some insight into the company's indirect impacts.
What are the main sources of SK Biopharmaceuticals's Scope 3 emissions?
In 2024, the largest contributors to SK Biopharmaceuticals's Scope 3 emissions were: a
- Purchased Goods and Services (Cat. 1): 7,769 tCO₂e (84.74%)
- Business Travel (Cat. 6): 854 tCO₂e (9.32%)
- Employee Commuting (Cat. 7): 289 tCO₂e (3.15%)
SK Biopharmaceuticals's Scope 3 Emissions by Categories
Insights into SK Biopharmaceuticals’s GHG Emissions Intensity Compared to Industry Peers
In 2024, SK Biopharmaceuticals reported Scope 1 greenhouse gas (GHG) emissions of 414 tCO₂e and total revenues of USD 373 millions. This translates into an emissions intensity of 1.11 tCO₂e per millions USD. a
SK Biopharmaceuticals's Scope 1 Emissions Intensity Compared to Peers
How does SK Biopharmaceuticals's GHG emissions intensity compare to its peers?
In 2024, SK Biopharmaceuticals reported a Scope 1 emissions intensity of 1.11 tCO₂e per millions USD. Compared to the peer group median of 4.17 , this places the company below its industry benchmark, indicating it is more carbon-efficient than most competitors. a
Where does SK Biopharmaceuticals rank on GHG emissions intensity within its industry?
In 2024, SK Biopharmaceuticals ranked 8 out of 24 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCO₂e per millions USD). a
SK Biopharmaceuticals is therefore positioned in the mid-range of its industry, neither a clear leader nor a laggard in carbon efficiency. a
Insights into SK Biopharmaceuticals's Total Carbon Footprint
In 2024, SK Biopharmaceuticals reported a total carbon footprint of 10,779 metric tons of CO₂ equivalent (tCO₂e) across Scope 1, Scope 2, and Scope 3 emissions. This represents a 19.33% decrease compared to 2023, indicating progress in reducing its overall greenhouse gas output. a b
The largest contributor to SK Biopharmaceuticals's total carbon footprint was Scope 3 emissions, accounting for 85.05% of the company's total carbon footprint, followed by Scope 2 emissions at 11.1%. a